|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2223242526272829303132...6768» |
- ||| New trial: OSA in EDS: Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome (clinicaltrials.gov) - May 7, 2015
P=N/A, N=100, Recruiting, Sponsor: University of Zurich
- peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change, Trial withdrawal, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
N=13 --> 0 | Not yet recruiting --> Withdrawn
- Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy: Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - May 6, 2015
P1, N=18, Recruiting, Sponsor: Weill Medical College of Cornell University
N=13 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Enrollment closed: PERSEPT 1: Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors (clinicaltrials.gov) - May 5, 2015
P3, N=25, Active, not recruiting, Sponsor: rEVO Biologics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | BeneFix (nonacog alfa) / Pfizer
Trial completion: An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B (clinicaltrials.gov) - May 5, 2015
P1, N=12, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Completed
- | PVX-410 / OncoPep
Enrollment closed, Trial primary completion date: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma (clinicaltrials.gov) - May 4, 2015
P1/2, N=22, Active, not recruiting, Sponsor: OncoPep, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Apr 2016
- || Trial primary completion date: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects (clinicaltrials.gov) - May 1, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Apr 2016 Trial primary completion date: Mar 2015 --> Mar 2016
- Trial initiation date, Trial primary completion date: PROPRIO-HE: Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: Universidad Católica San Antonio de Murcia
Trial primary completion date: Mar 2015 --> Mar 2016 Initiation date: Oct 2014 --> May 2015 | Trial primary completion date: Nov 2014 --> May 2015
- | Innohep (tinzaparin) / LEO Pharma
Enrollment open, Trial initiation date: METRO B: Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (clinicaltrials.gov) - Apr 28, 2015
P2, N=24, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Initiation date: Oct 2014 --> May 2015 | Trial primary completion date: Nov 2014 --> May 2015 Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Apr 2015
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
New trial, Surgery: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Apr 27, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: CSL Behring
- Trial termination: Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements. (clinicaltrials.gov) - Apr 27, 2015
P1, N=200, Terminated, Sponsor: University of Rochester
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Apr 2015 Recruiting --> Terminated; insufficient enrollment
- bortezomib / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change, Trial withdrawal: Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 25, 2015
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Terminated; insufficient enrollment N=43 --> 0 | Not yet recruiting --> Withdrawn
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=20, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=43 --> 0 | Not yet recruiting --> Withdrawn N=30 --> 20
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Apr 25, 2015
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=30 --> 20 Recruiting --> Active, not recruiting
- Enrollment open, Trial initiation date, Trial primary completion date: FOX-TREG: Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2015 | Trial primary completion date: Sep 2017 --> Feb 2017
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial primary completion date: GIMEMA Protocol ITP0207: Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Apr 22, 2015
P3, N=150, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2015 | Trial primary completion date: Sep 2017 --> Feb 2017 Trial primary completion date: Mar 2015 --> Mar 2016
- | prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Enrollment closed: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Apr 22, 2015
P3, N=62, Active, not recruiting, Sponsor: Ohio State University
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- Trial completion: NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=80, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- aspirin / Generic mfg.
New trial: High-Shear Microfluidic Thrombosis Assay (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=45, Enrolling by invitation, Sponsor: Emory University
- | imetelstat (GRN163L) / Geron
Trial completion, Enrollment change, Trial primary completion date: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Apr 21, 2015
P2, N=20, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013
- || Enrollment change, Trial primary completion date, Surgery: INWOUND: Wound Healing Abnormalities in Major Abdominal Surgery (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=260, Recruiting, Sponsor: Klinikum St. Georg gGmbH
Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013 N=200 --> 260 | Trial primary completion date: Dec 2015 --> Jun 2016
- |||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial primary completion date: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Apr 20, 2015
P3, N=106, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
N=200 --> 260 | Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Mar 2015 --> Jun 2015
- || afuresertib (LAE002) / Laekna Therap
Trial primary completion date, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - Apr 20, 2015
P1, N=90, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> May 2015
- Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial initiation date, Surgery: Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=26, Completed, Sponsor: Bayer
Trial primary completion date: Dec 2014 --> May 2015 Initiation date: Aug 2009 --> Aug 2008
- ||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Enrollment closed, Trial primary completion date: ARETA: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (clinicaltrials.gov) - Apr 20, 2015
P3, N=280, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Initiation date: Aug 2009 --> Aug 2008 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
P1 data: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) - Apr 19, 2015
P1, N=26, Recruiting, Sponsor: Spectrum Health Hospitals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Trial primary completion date: May 2015 --> Dec 2015
- Trial primary completion date: Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=40, Recruiting, Sponsor: Beth Israel Medical Center
Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: Apr 2015 --> Dec 2016
- lenalidomide / Generic mfg.
Trial primary completion date: Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Apr 19, 2015
P2, N=41, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2015 --> Dec 2016 Trial primary completion date: May 2015 --> Dec 2015
- || ALT-801 / ImmunityBio
Trial primary completion date: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 19, 2015
P1/2, N=66, Active, not recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: Aug 2014 --> Sep 2015
- albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 19, 2015
P2, N=30, Suspended, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2014 --> Sep 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- || alisertib (MLN8237) / Puma
Trial primary completion date: Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 19, 2015
P1/2, N=69, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Aug 2014 --> Aug 2015
- | Enrollment change, Trial primary completion date: RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma (clinicaltrials.gov) - Apr 17, 2015
P3, N=100, Recruiting, Sponsor: Medical University Innsbruck
Trial primary completion date: Aug 2014 --> Aug 2015 N=200 --> 100 | Trial primary completion date: Mar 2014 --> Dec 2016
- Darzalex (daratumumab) / J&J
New P2/3 trial: "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " (clinicaltrials.gov) - Apr 17, 2015
P2/3, N=50, Recruiting, Sponsor: Vejle Hospital
- | Xyntha (moroctocog alfa) / Pfizer
Enrollment open: Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients (clinicaltrials.gov) - Apr 17, 2015
P4, N=50, Recruiting, Sponsor: Pfizer
N=200 --> 100 | Trial primary completion date: Mar 2014 --> Dec 2016 Active, not recruiting --> Recruiting
- Enrollment change: ACUFOCIN: Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma (clinicaltrials.gov) - Apr 16, 2015
P2, N=120, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Active, not recruiting --> Recruiting N=20 --> 120
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Observational data, Enrollment change: Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=51, Completed, Sponsor: Novo Nordisk A/S
N=20 --> 120 Active, not recruiting --> Completed | N=40 --> 51
- simvastatin / Generic mfg.
Enrollment change: PSMMSS: Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma (clinicaltrials.gov) - Apr 16, 2015
P2a, N=0, Withdrawn, Sponsor: Meir Medical Center
Active, not recruiting --> Completed | N=40 --> 51 N=15 --> 0
- |||| bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment open: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 16, 2015
P1/2, N=69, Recruiting, Sponsor: Mayo Clinic
N=15 --> 0 Suspended --> Recruiting
- | bortezomib / Generic mfg.
Trial completion, Phase classification: ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. (clinicaltrials.gov) - Apr 16, 2015
P4, N=11, Completed, Sponsor: Janssen-Cilag B.V.
Suspended --> Recruiting Terminated --> Completed | Phase classification: PN/A --> P4
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 15, 2015
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed | Phase classification: PN/A --> P4 Active, not recruiting --> Completed
- Trial primary completion date: HERO: To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=200, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Jun 2015
- Trial termination: Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=75, Terminated, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Mar 2015 --> Jun 2015 Active, not recruiting --> Terminated; Unable to fill cohort
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2015
P1, N=12, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; Unable to fill cohort Trial primary completion date: Feb 2015 --> Aug 2015
- tabalumab (LY2127399) / Eli Lilly
Trial primary completion date, Combination therapy: Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2015
P1, N=10, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Feb 2015 --> Aug 2015 Trial primary completion date: Oct 2015 --> Feb 2015
- Quadramet (samarium 153 lexidronam) / Jazz
Trial primary completion date: Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=39, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2015 --> Feb 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2015
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- melphalan / Generic mfg.
Trial primary completion date: S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis (clinicaltrials.gov) - Apr 14, 2015
P2, N=100, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Jul 2014 --> May 2012
- || Trial primary completion date: Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (clinicaltrials.gov) - Apr 14, 2015
P2b, N=240, Active, not recruiting, Sponsor: PETHEMA Foundation
Trial primary completion date: Jul 2014 --> May 2012 Trial primary completion date: Nov 2014 --> Nov 2015
- || bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=110, Recruiting, Sponsor: Oncotherapeutics
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Sep 2014 --> Apr 2016
- || bortezomib / Generic mfg.
Trial primary completion date: Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens (clinicaltrials.gov) - Apr 14, 2015
P2, N=52, Recruiting, Sponsor: Oncotherapeutics
Trial primary completion date: Sep 2014 --> Apr 2016 Trial primary completion date: Aug 2014 --> Jul 2015